Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 10, 1997, Pages 3498-3505

  Labrie, Fernand ^a   Diamond, Pierre ^a   Cusan, Leonello ^a   Gomez, Jose Luis ^a   Bélanger, Alain ^a   Candas, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CREATININE; HYDROXYPROLINE; OSTEOCALCIN; PRASTERONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFECT; ENDOMETRIUM ATROPHY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MATURATION; OSSIFICATION; POSTMENOPAUSE; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; VAGINA EPITHELIUM;

POMACANTHUS MACULOSUS;

EID: 0030883203     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.10.4306     Document Type: Article

References (71)

1. Labrie C, Bélanger A, Labrie F. 1988 Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 123:1412-1417.
2. Labrie F. 1991 Intracrinology. Mol Cell Endocrinol. 78:C113-C118.
3. Labrie F, Dupont A, Bélanger A. 1985 Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott; 193-217.
4. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C. 1995 DHEA and peripheral androgen and estrogen formation: intracrinology. Ann NY Acad Sci. 774:16-28.
5. Labrie F, Simard J, Luu-The V, et al. 1996 The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson, V, Levy, FO and Taskén, K, eds. Signal transduction in testicular cells. Ernst Schering Research Foundation Workshop. Berlin, Heidelberg, New York: Springer-Verlag; vol suppl 2:185-218.
6. Labrie F, Luu-The V, Lin SX, et al. 1997 The key role of 17β-HSDs in sex steroid biology. Steroids. 62:148-158.
7. Migeon CJ, Keller AR, Lawrence B, Shepart II TH. 1957 Dehydroepiandresterone and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab. 17:1051-1062.
8. Orentreich N, Brind JL, Rizer RL, Vogelman JH. 1984 Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 59:551-555.
9. Vermeulen A, Deslypene JP, Schelthout W, Verdonck L, Rubens R. 1982 Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab. 54:187-191.
10. Bélanger A, Candas B, Dupont A, et al. 1994 Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 79:1086-1090.
11. Schriock ED, Buffington CK, Hubert GD, et al. 1988 Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 66:1329-1331
12. Coleman DL, Leiter EH, Schwizer RW. 1982 Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes. 31:830-833.
13. Barrett-Connor E, Khaw KT, Yen SS. 1986 A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med. 315:1519-1524.
14. Nestler JE, Barlascini CO, Clore JN, Blackard WG. 1988 Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 66:57-61.
15. MacEwen EG, Kurzman ID. 1991 Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr. 121:S51-S55.
16. Tchernof A, Després JP, Bélanger A, et al. 1995 Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism. 44:513-519.
17. Zumoff B, Levin J, Rosenfeld RS, et al. 1981 Abnormal 24-hr mean plasma concentrations of dehydroepiandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res. 41:3360-3363.
18. Stahl F, Schnorr D, Pilz C, Dorner G. 1992 Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol. 99:68-70.
19. Schwartz AG, Pashko L, Whitcomb JM. 1986 Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol. 14:357-362.
20. Gordon GB, Shantz LM, Talalay P. 1987 Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul. 26:355-382.
21. Li S, Yan X, Bélanger A, Labrie F. 1993 Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat. 29:203-217.
22. Suzuki T, Suzuki N, Daynes RA, Engleman EG. 1991 Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol. 61:202-211.
23. Rasmusson KR, Arrowood MJ, Healey MC. 1992 Effectiveness of dehydroepiandrosterone in reduction of cryptosporidial activity in immunosuppressed rats. Antimicrob Agents Chemother. 36:220-222.
24. Casson PR, Andersen RN, Herrod HG, et al. 1993 Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 169:1536-1539.
25. Johnston Jr CC, Epstein S. 1981 Clinical, biochemical, radiographic, epidemiologic, and economic features of osteoporosis. Orthop Clin North Am. 12:559-569.
26. Bardon S, Vignon F, Chalbos D, Rochefort H. 1985 RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab. 60:692-697.
27. Colditz GA, Hankinson SE, Hunter DJ, et al. 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1589-1593.
28. Dupont A, Dupont P, Cusan L, et al. 1991 Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in postmenopausal women. Maturitas. 13:297-311.
29. Dupont A, Dupont P, Cusan L, et al. 1992 Efficacy of percutaneous estradiol and oral estrogens as replacement therapy in postmenopausal women. In: Dusitsin N, Notelovitz M, eds. Physiological hormone replacement therapy. Park Ridge, NJ: Parthenon; 37-50.
30. Heinegard D, Tiderstrom G. 1973 Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta. 43:305-310.
31. Podenphant J, Larsen NE, Christiansen C. 1984 An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta. 142:145-148.
32. Franceschi S. 1990 The epidemiology of endometrial cancer. Gynecol Oncol. 41:1-16.
33. Friedl A, Jordan VC. 1994 What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat. 31:27-39.
34. Chen C, Li X, Singh SM, Bélanger A, Labrie F. 1996 Additive in vivo growth inhibitory effects of flutamide and finasteride on androgen-sensitive shionogi 115 carcinoma. Endocr Relat Cancer. 3:217-227.
35. Luu-The V, Sugimoto Y, Puy L, et al. 1994 Characterization, expression and immunohistochemical localization of 5α-reductase in human skin. J Invest Dermatol. 102:221-226.
36. 4-androstenedione and dehydroisoandrosterone. J Invest Dermatol. 52:32-36.
37. 4 isomerase in human skin. J Invest Dermatol. 99:415-421.
38. Baillie AH, Thomson J, Milne JA. 1966 The distribution of hydroxysteroid dehydrogenase in human sebaceous glands. Br J Dermatol. 78:451-457.
39. Chen C, Bélanger A, Labrie F. 1996 Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Endocrinology. 137:1752-1757.
40. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. 1994 Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 61:281-287.
41. Cusan L, Dupont A, Bélanger A, et al. 1990 Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol. 23:462-469.
42. Morales AJ, Nolan JJ, Nelson JC, Yen SS. 1994 Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 78:1360-1367.
43. Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. 1996 Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol. 150:543-550.
44. Mashchak CA, Lobo RA, Dozono-Takano R, et al. 1982 Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 144:511-518.
45. Lobo RA. 1987 Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am. 14:143-167.
46. Sherwin BB, Gelfand MM, Schucher R, Gabor J. 1987 Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. Am J Obstet Gynecol. 156:414-419.
47. Burger H, Hailes J, Nelson J, Menelaus M. 1987 Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J Clin Res Ed. 294:936-937.
48. Parker CR, Simpson ER, Bilheimer DW, et al. 1980 Inverse relation between low-density lipoprotein-cholesterol and dehydroisoanrosterone sulfate in human fetal plasma. Science. 208:512-514.
49. Marin P, Holmang S, Gustafsson C, et al. 1993 Androgen treatment of abdominally obese women. Obes Res. 1:245-251.
50. Marin P, Holmang S, Jonsson L, et al. 1992 The effects of testosterone treatment on body composition and metabolism in middle-aged obese women. Int J Obes. 16:991-997.
51. Rebuffe-Scrive M, Marin P, Bjorntorp P. 1991 Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 15:791-795.
52. Weinstein L, Bewtra C, Gallagher JC. 1990 Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol. 162:1534-1542.
53. Tikkanen MJ, Nikkila EA, Vartiainen E. 1978 Natural oestrogen as an effective treatment for type II hyperlipoproteinaemia in postmenopausal women. Lancet. 2:490-491.
54. Thorogood M, Carter R, Benfield L, McPherson K, Mann JI. 1987 Plasma lipids and lipoprotein cholesterol concentrations in people with different diets in Britain. Br Med J. 295:351-353.
55. Studd JW, Collins WP, Chakravarti S, et al. 1987 Estradiol and testosterone implants in treatment of psychosexual problems in postmenopausal woman. Br J Obstet Gynecol. 84:314-315.
56. Burger HG, Hailes J, Menelaus M, et al. 1984 The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas. 6:351-358.
57. Davis SR, McCloud P, Strauss BJ, Burger H. 1995 Testosterone enhances estradiol's effects on postmenopausal density and sexuality. Maturitas. 21:227-236.
58. Hennernan PM, Wallach S. 1957 The role of androgens and estrogens and their metabolic effects. A review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis. Arch Intern Med. 100:715-723.
59. Savvas M, Studd JWW, Fogelman I, et al. 1988 Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J. 297:331-333.
60. Need AG, Horowitz M, Bridges A, Morris HA, Nordin BE. 1989 Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch Intern Med. 149:57-60.
61. Prestwood KM, Pilbeam CC, Burleson JA, et al. 1994 The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 79:366-371.
62. Christiansen C, Christensen MS, Larsen NE, Transbol IB. 1982 Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab. 55:1124-1130.
63. Christiansen C. 1994 The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil Steril. 62:152S-156S.
64. Rosner W. 1990 The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocr Rev. 11:80-91.
65. De Fazio J, Meldrum DR, Winer JH, Judd HL. 1984 Direct action of androgen on hot flushes in the human male. Maturitas. 6:3-8.
66. Sherwin BB, Gelfand MM. 1984 Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol. 148:552-557.
67. Sherwin BB, Gelfand MM. 1987 The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med. 49:397-409.
68. Sherwin BB, Gelfand MM. 1985 Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 151:153-160.
69. Sherwin BB. 1988 Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 14:177-187.
70. Labrie F, Bélanger A, Cusan L, Candas B. 1997 Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab. in press.
71. 19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 82:2396-2402.